ACT Brief: AI Partnerships, Global Trial Access, and a New Option for Menopause Symptoms

from Applied Clinical Trials · host Applied Clinical Trials

In today’s ACT Brief, we spotlight expanding AI collaborations transforming life sciences, the role of patient-centric technology in improving global trial diversity, and the FDA’s approval of Bayer’s Lynkuet—the first dual neurokinin antagonist for menopausal hot flashes.

Episode metadata supplied by the publisher feed · Published Oct 27, 2025

Embed this episode

Attribution link and audio player

Ready to play

ACT Brief: AI Partnerships, Global Trial Access, and a New Option for Menopause Symptoms

0:00 2:33

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Applied Clinical Trials?

This episode is 2 minutes long.

When was this Applied Clinical Trials episode published?

This episode was published on October 27, 2025.

Can I download this Applied Clinical Trials episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!